Abstract

Treatment with Tyrosine Kinase Inhibitors (TKIs) in patients with metastatic Colorectal Cancer (CRC) is not widespread and it is not frequent to find targetable oncogenic genetic alterations. ALK fusions exhibit a very low incidence in CRC. We present the case of a 31-year-old woman in whom an ALK-EML4 fusion was identified. After progressing to two chemotherapy-based treatments, he received a treatment sequence with alectinib and lorlatinib. Although she presented an important response at the beginning, with a significant improvement in his quality of life, the duration of the response was lesser than expected, compared to those obtained in lung adenocarcinoma with ALK fusion. Further studies are warranted to better characterize these patients and design fitting therapeutic strategies that are adapted to their particularities.

Keywords: Colorectal cancer; Genetic alterations; Chemotherapy; Adenocarcinoma

Abbreviations:TKIS: Treatment with Tyrosine Kinase Inhibitors; CRC: Colorectal Cancer; ALK: Anaplasic Lymphoma Kinase; TKIS: Tyrosine Kinase Inhibitors; CT: Computerized Tomography